Compare Incyte Corporation (INCY) vs Microsoft (MSFT) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Incyte Corporation vs Microsoft — how do they compare? Incyte Corporation trades at $120.45 (market cap $24.65B), while Microsoft trades at $499.17 (market cap $3.76T). The key difference: Microsoft is far larger — about 152.5× Incyte Corporation's market cap, and Microsoft pays a 0.72% dividend while Incyte Corporation pays none. Which is the better fit depends on your goals.
| INCY | MSFT | |
|---|---|---|
Market Cap | $24.65B | $3.76T |
Sector | Health | Technology |
52-Week High | $129.93 | $542.07 |
52-Week Low | $81.61 | $352.83 |
Enterprise Value | $20.15B | $3.74T |
Volume | — | 36,654,621 |
Dividend Yield | — | 0.72% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Incyte Corporation (INCY) trades at $120.56, up 1.84% on the day, near its 52-week high of $120.70. The stock shows a bullish technical trend with strong earnings beats in Q1 and Q2 2026, including Q2 EPS of $3.09 versus $2.15 expected. Revenue growth accelerated to $5.14 billion in 2025, with a net income margin of 27.71%. Recent news highlights EU approval for Opzelura and a raised 2026 revenue outlook, fueling positive momentum.
The outlook remains favorable with analyst consensus at Buy and a $122.82 price target, though risks include reliance on key drugs like Jakafi and competitive pressures. Earnings growth and pipeline advancements support upside, but investors should monitor execution against guidance and regulatory developments.
Microsoft (MSFT) trades at $506.06, up 1.21% with strong technical momentum and bullish moving average signals. The company demonstrates robust fundamentals with $281.72B revenue, 40.31% net margin, and consistent earnings beats. Analyst consensus remains overwhelmingly positive with 80.49% buy ratings and $552.73 price target, representing 9.2% upside potential. Recent news highlights Microsoft's AI leadership and cloud computing strength.
Microsoft presents a compelling investment case with strong financial performance and AI-driven growth prospects. Key opportunities include Azure cloud expansion and Copilot adoption, while risks involve increased capital expenditures and competitive pressures. The stock's current valuation at 28.19 P/E appears reasonable given growth trajectory, though investors should monitor execution on AI investments and macroeconomic conditions affecting tech spending.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Incyte Corporation
Incyte focuses on the discovery and development of small-molecule drugs. The firm's lead drug, Jakafi, treats two types of rare blood cancer and graft versus host disease and is partnered with Novartis. Incyte's other marketed drugs include rheumatoid arthritis treatment Olumiant (licensed to Lilly), and oncology drugs Iclusig (chronic myeloid leukemia), Pemazyre (cholangiocarcinoma), Tabrecta (lung cancer), and Monjuvi (diffuse large B-cell lymphoma). The firm's first dermatology product, Opzelura, was approved in 2021 for atopic dermatitis. Incyte's pipeline includes a broad array of oncology and dermatology programs.
Read more on INCY →About Microsoft
Microsoft Corporation develops, manufactures, licenses, sells, and supports software products. The Company offers operating system software, server application software, business and consumer applications software, software development tools, and Internet and intranet software. Microsoft also develops video game consoles and digital music entertainment devices.
Read more on MSFT →
